ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2016 Financial Results
January 20 2016 - 8:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
biotechnology company that develops novel anticancer therapeutics
using its antibody-drug conjugate (ADC) technology, today announced
that the Company will host a conference call at 8:00 a.m. ET on
Friday, January 29, 2016, to discuss ImmunoGen's financial results
for the three-month period ended December 31, 2015. Management also
will provide an update on the Company.
To access the live call by phone, dial 913-312-0836; the
conference ID is 5851737. The call also may be accessed through the
Investors section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available
at the same location through February 12, 2016.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted anticancer therapeutics with its proprietary ADC
technology. The Company’s lead product candidate, mirvetuximab
soravtansine, is a potential treatment for folate receptor
α-positive ovarian cancers and other solid tumors. A number of
major healthcare companies have licensed limited rights to use
ImmunoGen’s ADC technology to develop novel anticancer therapies;
it is used in Roche’s marketed product, Kadcyla®. More information
about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member
of the Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160120005197/en/
ImmunoGen, Inc.Carol Hausner, 781-895-0600info@immunogen.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024